United-Guardian Receives FDA Approval to Market New Single-Dose Form of Renacidin®
04 Januar 2016 - 3:00PM
United-Guardian, Inc. (NASDAQ:UG) announced today that it has
received FDA approval of its Supplemental New Drug Application to
market a new single-dose form of Renacidin® (Citric Acid, Glucono
delta-Lactone, and Magnesium Carbonate), the company’s proprietary
irrigating solution that is used to prevent and dissolve
calcifications in indwelling catheters. The newly-approved drug
product will be supplied in a 30mL single-use plastic bottle, and
will replace the company’s 500mL glass bottle. The company expects
to have the new product available for distribution in March or
April 2016.
Ken Globus, President of United-Guardian stated,
“We are extremely pleased to finally receive FDA approval to market
Renacidin in a more user-friendly bottle. Over the many years that
Renacidin has been on the market we have received numerous requests
to bring to market a ready-to-use, single-dose unit. The new bottle
will enable the user to dispense the product directly into a
catheter without having to use a separate syringe. We believe that
this new single-dose unit will make the product much easier for
both medical professionals and caregivers to use, and are very
pleased to finally be able to offer this easier-to-use product to
the thousands of patients who depend on it.”
United-Guardian, Inc. is a manufacturer of
pharmaceuticals, cosmetic ingredients, personal care and health
care products. For more information about Renacidin please visit
the company’s web site at www.u-g.com, or contact the company at
1-800-645-5566.
NOTE: This press release contains both
historical and "forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements about the company’s expectations or beliefs concerning
future events, such as financial performance, business prospects,
and similar matters, are being made in reliance upon the “safe
harbor” provisions of that Act. Such statements are subject to a
variety of factors that could cause our actual results or
performance to differ materially from the anticipated results or
performance expressed or implied by such forward-looking
statements. For further information about the risks and
uncertainties that may affect the company’s business please refer
to the company's reports and filings with the Securities and
Exchange Commission.
Contact:
Robert S. Rubinger
Public Relations
(631) 273-0900
United Guardian (NASDAQ:UG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
United Guardian (NASDAQ:UG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024